ALHC · Alignment Healthcare, Inc.

The thesis

Alignment Healthcare is a Medicare Advantage insurer whose largest plan lost its 4-star quality rating on 8 October 2026, and the shares are more likely to lag the S&P 500 until the third-quarter report shows whether medical costs are contained. The company confirmed it will report after the market close on 29 October 2026, with a call at 5 p.m. Eastern. The shares closed at $8.05 on 27 October 2026, down 56.7% over three months and 67.2% below the 52-week high of $24.56.

The narrative is saturated: analysts cut targets on 9 October 2026 and 12 October 2026, and the cost and accounting questions raised in September and July remain open. According to a TIKR report, CMS's 2027 star ratings cut the California HMO contract H3815, which serves about 75% of health plan members, to 3.5 stars from 4.0. Quality bonuses require 4 stars or more.

The company says it expects no revenue effect in 2026 or 2027, so the cost lands on 2028 bonus payments. This view is wrong if the report shows third-quarter adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, as the company defines it) at or above the top of the $20 million–$30 million range with full-year guidance intact.

Bullish and bearish views on Alignment Healthcare, Inc.

The bull case on Alignment Healthcare, Inc. (ALHC), in brief: Near-term revenue is untouched. The bear case: The rating loss hits the core contract.

Bull case

• Near-term revenue is untouched. The company said on 9 October 2026 that it expects no revenue impact in 2026 or 2027 from the rating change, per TIKR. It also said provider risk-sharing should offset part of the 2028 effect.
• Second-quarter results were strong. The 30 July 2026 release showed revenue of $1,335.6 million, up 31.6% year over year, GAAP net income of $36.6 million and adjusted EBITDA of $68.1 million.
• Guidance stood unchanged at last check. Chief Financial Officer Jim Head said on 15 September 2026 that third-quarter adjusted EBITDA of $20 million–$30 million and full-year $145 million–$163 million were unchanged.
• Several analysts keep positive ratings. TD Cowen kept Buy and lowered its target to $12 on 12 October 2026. KeyBanc's target is $12 and JPMorgan's is $10, both cut on 9 October 2026. All sit above the $8.05 close.
• Member-facing news is favourable. On 20 October 2026 U.S. News & World Report named Alignment Health Plan its 2027 Best Insurance Company for Medicare Advantage, and the plan announced a California care partnership with Astrana Health. Enrollment opened 15 October 2026.
• An appeal route exists. Management said it is confident of returning the California contract to at least 4 stars, per TIKR. No appeal outcome or date has been reported.

Bear case

• The rating loss hits the core contract. H3815 carries about 75% of health plan members and fell below the 4-star bonus threshold on 8 October 2026, per TIKR. Management attributed the drop to higher industry cut points and weaker results on heavily weighted survey and Part D measures.
• Analysts are cutting. William Blair downgraded the shares to Market Perform on 9 October 2026. UBS kept Neutral and lowered its target to $9 on 12 October 2026.
• Medical costs ran above plan. On 15 September 2026 Head cited hospital-billing disputes and skilled-nursing cost pressure. Third-quarter adjusted EBITDA guidance of $20 million–$30 million compares with $68.1 million in the second quarter. Management had also guided to a seasonally higher medical cost ratio in the third quarter.
• The accounting allegation is open. A former executive's complaint, reported by Modern Healthcare on 8 July 2026, alleges $8 million–$10 million of operating expenses were reclassified as capital spending to lift adjusted EBITDA. Plaintiff firms have announced investigations; those releases are solicitations and do not establish merit.
• The article gives no sale date.

Price setup

The adjusted daily close was $8.05 on 27 October 2026, against $8.23 on 14 October 2026 and $7.74 on 1 October 2026. The 14-day relative strength index (RSI, a 0–100 momentum gauge) was 42.6, down from 55.9 on 14 October 2026. The shares sit 67.2% below the 52-week high of $24.56 and well under it on every recent measure, so there is no gap above a rising moving average.

Crowding evidence is mixed. Heavy analyst and plaintiff-firm attention is visible, an earnings date falls within two sessions, and an executive sale was reported on 24 September 2026. No share issuance is reported in company filings in the period.

Chartmill reports analyst estimates of a loss of $0.03 per share and revenue of $1.339 billion for the third quarter. The company's own revenue guidance, per EarningsWhispers' summary of the second-quarter report, is $1.30 billion–$1.32 billion. The $7.00 level sits below the 1 October 2026 close of $7.74.

Catalysts, next 30 days

• Through 7 December 2026: Medicare annual enrollment period. Membership results appear in the first-quarter 2027 report, not before.
• Undated: Company appeal of the H3815 rating and the planned legal action over CMS's methodology. No filing date has been reported.

Elapsed catalysts

• 29 October 2026, after the close: Third-quarter 2026 results and 5 p.m. Eastern call. They test the $20 million–$30 million adjusted EBITDA guidance and the $145 million–$163 million full-year range, and may quantify the 2028 star-rating offset. (passed 8d ago)

What would change the view

The low-conviction read breaks if the 29 October 2026 report shows third-quarter adjusted EBITDA at or above $30 million, full-year guidance of $145 million–$163 million held or raised, and a quantified 2028 offset that analysts accept. A medical cost ratio that improves from the second quarter would carry the same weight. It also breaks on a reported win in the appeal of H3815.

The case turns worse on a cut to full-year guidance, third-quarter adjusted EBITDA under $20 million, or a restatement tied to the capitalization allegation. A daily close below $7.00 would also end the recovery case.

What it trades with

Alignment trades with other Medicare Advantage insurers on CMS payment and star-rating news, and on medical cost trend commentary from larger peers. Its California concentration and the H3815 contract make the 8 October 2026 rating a company-specific driver on top of that sector move. No peer data is cited here, and the sample of post-downgrade sessions is too small to draw a conclusion about sector sensitivity.